Major Depressive Disorder (MDD), also referred as clinical depression, is a mental health condition that affects sleep, mood, appetite, and behavior. The specific cause of MDD is unknown; moreover, a combination of genes and stress that affects brain chemistry and reduces the ability to maintain emotional stability are two factors that can increase the risk. MDD can be caused by hormonal imbalances, alcohol or drug misuse, some medical disorders such as cancer or hypothyroidism, and various prescription side effects such as steroids.
Changing lifestyles, including as job pressure and alcohol addiction, have resulted in an increase in the prevalence of MDD, which is projected to fuel major depressive disorder treatment market growth throughout the forecast period. MDD is the most frequent psychiatric disorder in India, according to an article published in the National Center for Biotechnology Information in 2015 and the lifetime prevalence of MDD is 5–12 % for men and 10–25 % for women.
The global major depressive disorder (MDD) treatment market is expected to rise in the near future as the U.S. Food and Drug Administration (FDA) approves more new drugs.
Ask for PDF sample copy of the Major Depressive Disorder (MDD) Treatment market report @ https://www.coherentmarketinsights.com/insight/request-pdf/1217
The global major depressive disorder (MDD) treatment market is undergoing a transformation, with patents for drugs such as Cymbalta and Abilify recently expiring, and revenue from these drugs declining as generics have become available. As a result, new drug approvals such as Levomilnacipran, Brintellix, and Rexulti (brexpiprazole) are a major driver of market growth. In 2013, the U.S. FDA approved levomilnacipran, a novel serotonin-norepinephrine reuptake inhibitor (SNRI), for individuals with major depressive disorder (MDD).
Takeda Pharmaceutical Company Limited and H. Lundbeck A/S announced that Brintellix (vortioxetine) has received the U.S. FDA approval for the treatment of adults with major depressive disorder (MDD). In July 2015, the U.S. FDA approved Rexulti (brexpiprazole) tablets as an add-on treatment to an antidepressant drug for adults with major depressive disorder (MDD). These approvals are expected to give patients suffering from MDD more options, which will help the global major depressive disorder (MDD) treatment market grow.
Due to increasing prevalence of major depressive disorder, North America is expected to hold the dominant position in the global major depressive disorder (MDD) treatment market over the forecast period
North America is expected to hold the dominant position in the major depressive disorder (MDD) treatment market due to rising incidences of major depressive disorder in the U.S. According to the National Institute of Mental Health, In 2015, an estimated 16.1 million adults in the U.S. aged 18 and above had at least one major depressive episode in the past year, accounting for 6.7 percent of all adults in the U.S. Due to the speedy approval of new drugs by regulatory bodies, Europe is expected to be the second largest market for major depressive disorder treatment. Soterix Medical, for instance, received CE Marking in 2015 for its novel tDCS depressive disorder therapy, which is used to treat MDD.
Buy Now this Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/1217
Reasons to Purchase this Report
• Current and future of global Major Depressive Disorder (MDD) Treatment market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
“Limited Time Offer”
Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.
We also offer 15% FREE Report customization.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/1217
Major players operating in the global major depressive disorder (MDD) treatment market include Alkermes, Johnson & Johnson, AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited., Sanofi S.A., Allergan, Eli Lilly and Company, Lundbeck, Pfizer, Inc., and Merck & Co.
Table of Content
Global Major Depressive Disorder (MDD) Treatment Market Research Report
Section 1: Global Major Depressive Disorder (MDD) Treatment Industry Overview
Section 2: Global Economic Impact on Major Depressive Disorder (MDD) Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Major Depressive Disorder (MDD) Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Major Depressive Disorder (MDD) Treatment Market Forecast
Other Exclusive Reports:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027